Talazoparib

June 26, 2019

European Commission Approves Talzenna to Treat Some Breast Cancers

News

The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy ... Read more

October 19, 2018

FDA Approves Talzenna to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Talzenna (talazoparib) for the treatment of HER2-negative advanced breast cancer in adult patients with inherited BRCA mutations. The FDA also stated that patients’ eligibility for ... Read more

June 15, 2018

Talazoparib, Potential Treatment for Metastatic Breast Cancer with BRCA Mutations, Up for US and EU Approval

News

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Pfizer’s application for talazoparib, a candidate for the treatment of metastatic breast cancer in patients ... Read more

May 14, 2018May 14, 2018

Study Discovers Mutations That Cause Resistance to Lynparza, Similar Therapies

News

Researchers have identified mutations in the poly (ADP-ribose) polymerase (PARP) gene that cause resistance to the cancer therapy Lynparza (olaparib) and other PARP inhibitors. These mutations could help physicians predict which cancer ... Read more

December 18, 2017

Talazoparib Prevented Disease Progression in Breast Cancer with BRCA Mutations in Phase 3 Trial

News

Pfizer’s talazoparib prolonged the time until disease progression or death in breast cancer patients with inherited BRCA mutations, compared to standard chemotherapy, in a Phase 3 trial of the treatment. ... Read more